Mitsubishi Chemical Holdings Corp banner

Mitsubishi Chemical Holdings Corp
F:M3C

Watchlist Manager
Mitsubishi Chemical Holdings Corp Logo
Mitsubishi Chemical Holdings Corp
F:M3C
Watchlist
Price: 5.754 EUR 0.24% Market Closed
Market Cap: €8.2B

Mitsubishi Chemical Holdings Corp
Investor Relations

Mitsubishi Chemical Holdings is the parent company of a large Japanese chemical group. Through its operating businesses, it makes basic chemicals, plastics, specialty materials, carbon fiber, battery and electronic materials, and healthcare-related products. These are the kinds of inputs that other companies use to make cars, phones, packaging, construction materials, industrial parts, and medical products. Its main customers are manufacturers and industrial buyers rather than ordinary consumers. The company sells materials and chemical products directly to factories and other businesses, and it also has healthcare and pharmaceutical activities that sell through medical and commercial channels. In simple terms, it makes money by turning raw materials and chemical know-how into products that sit near the start of many supply chains. What makes the business different is its role as a materials supplier, not a finished-goods brand. Many of its products are designed to meet very specific technical needs, such as strength, heat resistance, purity, or electrical performance. That gives the company a place in industries that need reliable, specialized inputs rather than everyday consumer products.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2026
Call Date
Feb 5, 2026
AI Summary
Q3 2026

Revenue Decline: Mitsubishi Chemical Group's Q3 FY25 revenue fell 8% year-on-year to JPY 2,737.3 billion, mainly due to weak demand and business restructuring.

Profit Volatility: Core operating income for the first nine months dropped 2% year-on-year, but net income attributable to owners surged 77% due to asset sales, notably Mitsubishi Tanabe Pharma.

Guidance Cut: Full-year profit forecast was sharply reduced from JPY 125 billion to JPY 47 billion, reflecting additional nonrecurring losses tied to business exits and structural reforms.

Business Exits: The group decided to withdraw from coke and carbon materials businesses, incurring significant impairment and dismantling costs.

Dividend Maintained: Despite earnings revisions, the company kept its annual dividend forecast unchanged at JPY 32 per share.

Segment Trends: Specialty Materials outperformed with higher profits despite lower sales, while MMA & Derivatives and Basic Materials saw sharp declines.

Cost Reductions: Substantial cost reduction efforts contributed positively, especially in Industrial Gases and Chemicals.

Mixed Outlook: Management expects Q4 to be supported by strong semiconductor demand and improved carbon products profitability, but some segments remain challenged.

Key Financials
Revenue
JPY 2,737.3 billion
Core Operating Income
JPY 185.6 billion
Core Operating Income (Chemicals)
JPY 41.2 billion (first 9 months)
Net Income Attributable to Owners
JPY 105.4 billion
Special Items
net loss of JPY 72.3 billion
Operating Income
JPY 113.3 billion
Free Cash Flow
JPY 370.8 billion
Dividend per Share
JPY 32 per share (annual), JPY 16 per share (year-end)
Net Interest-Bearing Debt
decreased by JPY 324 billion from previous fiscal year end
Net D/E Ratio
0.83
Core Operating Income (Q3 only)
JPY 59.5 billion
Earnings Call Recording
Other Earnings Calls

Management

Mr. Ken Fujiwara
Executive VP, General Counsel & Director
No Bio Available
Frank Randall Queen
Executive VP & Head of Specialty Materials
No Bio Available
Mr. Manabu Chikumoto
President, CEO, Representative Corporate Executive Officer & Director
No Bio Available
Mr. Minoru Kida
VP & CFO
No Bio Available
Toshiya Katsuragi
Senior VP & CTO
No Bio Available
Isao Yano
Senior VP & Chief Compliance Officer
No Bio Available
Mr. Osamu Shimizu
General Manager of Corporate Communications Office
No Bio Available
Masahiko Tanaka
VP & Chief Human Resource Officer
No Bio Available
Mr. Yuji Ichimura
Senior VP & Chief Digital Officer
No Bio Available
Mr. Akihiro Tsujimura M.B.A.
Executive VP & Head of Pharma
No Bio Available

Contacts

Address
TOKYO-TO
Chiyoda-ku
Palace Bldg., 1-1-1, Marunouchi
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett